SAR442970
Sponsors
Sanofi-Aventis Recherche & Developpement, Sanofi
Conditions
Crohn's DiseaseCrohn’s diseaseHidradenitis SuppurativaImmune system diseasesUlcerative Colitis
Phase 2
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
CompletedNCT05849922
Start: 2023-06-06End: 2025-01-09Updated: 2026-01-29
A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)
RecruitingCTIS2024-511775-15-00
Start: 2025-01-17Target: 40Updated: 2025-12-15
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
RecruitingNCT06958536
Start: 2025-06-03End: 2029-10-17Target: 99Updated: 2026-03-27
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
RecruitingNCT06975722
Start: 2025-07-07End: 2029-10-17Target: 99Updated: 2026-03-27
A Phase 2, multicenter, randomized, double-blind, placebo controlled, dose-ranging study to evaluate the efficacy and safety of SAR442970 in adults with moderate to severe Crohn’s disease
RecruitingCTIS2024-517016-30-00
Start: 2025-09-26Target: 30Updated: 2025-08-12
A Phase 2b multi-national, multi-center, randomized, double-blind, placebo-controlled, dose-ranging study followed by a long-term extension to evaluate the efficacy and safety of SAR442970 in adult participants with moderate to severe ulcerative colitis.
RecruitingCTIS2024-515241-41-00
Start: 2025-09-10Target: 57Updated: 2025-08-12